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Background: Precipitating factors leading to exacerbation of
chronic HF are often not directly related to the evolution of cardiac
disease. The aim of this study was to examine prospectively the
precipitating factors leading to hospitalization of patients with
chronic HF.
Method: Potential risk factors that led to cardiac decompensation
and subsequent hospitalization were studied in 346 patients
between June 2013 to June 2015. Decompensation was deﬁned
as the worsening in the clinical NYHA class associated with the
need for an increase in medical treatment (requiring at least iv
diuretics).
Result: Themean agewas 58  14years, 48% of patientwere female
and mean ejection fraction was 36%. One or more precipitating
factors were identiﬁed in 84% of patients, nonadherence to diet
(13%) or medications (22%) or to both (19%) was the most com-
monly identiﬁed precipitating factor (54%). Other precipitating
factors were infections (16%), arrhythmias (17%), acute coronary
ischemia (18.5%), and uncontrolled hypertension (2%). Miscella-
neous causes were detected in 8% of cases (progression of renal
disease 3%, anemia 2% and iatrogenic factors including usage of
NSAIDs 3%).
Conclusion: Precipitating factor are frequently identiﬁed in
patients hospitalized for HF. Many of these risk factors are avoid-
able and their identiﬁcation is important in optimizing the man-
agement of HF. Patient noncompliance with prescribed medical
regime accounts for more than half of the HF decompensation in
this study. Thus patient education is very important to improve
compliance and thereby minimize recurrent hospital admissions.
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A middle aged male patient diagnosed with B-cell non-Hodg-
kin's lymphoma and was treated with rituximab, doxorubicin,
vincristine, and cyclophosphamide (R-CHOP) chemotherapy
regimen for 6 months. Four months after the chemotherapy,
patient presented with symptoms of heart failure. There was no
signiﬁcant history of any cardiac disease in the past. Chest X-ray
was done which showed enlarged cardiac silhouette. Echocar-
diography was done which revealed a dilated cardiomyopathy
with severe left ventricular (LV) systolic dysfunction. Chest X ray
before starting the chemotherapy had normal cardiac silhouette.
Echocardiography reports before starting the chemotherapy
were with normal limits with normal sized heart and normal
ejection fraction. Patient was managed with optimal drugs and
echocardiography was repeated after 1 year which showed an
improved LV systolic function with ejection fraction of around
40%. This led to the diagnosis of doxorubicin-induced cardio-
myopathy.
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Introduction: Heart failure is currently appreciated as a systemic
and other multi-organ syndrome. The myocardium, peripheral
tissues and organs are affected by metabolic failure, resulting in
a global imbalance between catabolic and anabolic signals, leading
to tissue wasting and, ultimately, to cachexia.
Cachexia is recognized today as severe complication of CHF that
worsens clinical symptoms and carries a particularly grave prog-
nosis. Mortality in HF patients with cachexia was as high as 50% at
18 months of follow-up, compared with 17% in cachectic patients
(48).
Pathophysiology:
(A) The neuroendocrine activation – it is the cornerstone of current
pathophysiological understanding of heart failure
(B) Inﬂammatory activation
(C) Metabolic impairment – metabolic regulation is increasingly
recognized as contributing both to major symptoms (muscle
weakness, fatigue, exercise limitation, and dyspnea) and to
disease progression
Anabolic failure: The normal anabolic response to insulin and
amino acid stimulation was reduced in HF patients by more than
50% because of both a blunted protein anabolic response and
increased proteolysis.
Catabolic activation: Catabolic activation is particularly apparent
in adipose tissue, as several independent pathways exert lipolytic
signals on hormone-sensitive lipase.
Insulin resistance: The normal anabolic response to insulin and
amino acid stimulation was reduced in HF patient by more than
50%, because of both a blunted protein anabolic response and
increased proteolysis. Even in nondiabetic patients, insulin resis-
tance in HF progresses in parallel to HF severity and predicts
impaired functional capacity of cardiovascular and particularly
of muscle function.
Skeletal muscle: Skeletal muscle is the main effector organ for
physical activity and the body's largest amino acid storage pool.
Summary:
 Heart failure
 Metabolic failure
 Catabolic dominance signals
 Anabolic blunted signals
 Tissue wasting
 Cardiac cachexia
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